The Inappropriate Use of Proton Pump Inhibitors: An Internal Medicine Residency Clinics Effort to Deprescribe

Polina Gaisinskaya1*, Zed Seedat1, Sanja Patino1, Navneet Kaur1,3, Oscar L. Hernandez1, Eric Abkian1, Jamie Fabricant1, Mishah Azhar1, Michael A. DeDonno2, Nabil Benhayoun1 1Department of Internal Medicine, Florida Atlantic University, Boca Raton, FL, USA 2Division of Educational Leadership and Research Methodology, Florida Atlantic University, Boca Raton, FL, USA 3Pulmonary and Critical Care Medicine, University of Southern California, CA, USA *Correspondence should be addressed to Polina Gaisinskaya; pgaisinskaya@health.fau.edu

[1]  Y. Hadi,et al.  “Get Me Off This Medication!”: A Comparison Between Gastroenterology and Primary Care Regarding Patient’s Perceptions of Proton Pump Inhibitor Therapy , 2020, Cureus.

[2]  L. Surry,et al.  Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic , 2020, Cureus.

[3]  R. Fossmark,et al.  Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility , 2019, International journal of molecular sciences.

[4]  D. Corley.  Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. , 2019, Gastroenterology.

[5]  Deepak L. Bhatt,et al.  Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. , 2019, Gastroenterology.

[6]  J. Alexander,et al.  Proton Pump Inhibitors: Review of Emerging Concerns , 2018, Mayo Clinic proceedings.

[7]  Candy S. Lee,et al.  Outcome after Discontinuation of Proton Pump Inhibitors at a Residential Care Site: Quality Improvement Project. , 2017, The Canadian journal of hospital pharmacy.

[8]  D. Freedberg,et al.  The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. , 2017, Gastroenterology.

[9]  Jennifer S. Haas,et al.  Trends in Prescription Drug Use Among Adults in the United States From 1999–2012 , 2016 .

[10]  C. Frenette,et al.  Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. , 2015, JAMA internal medicine.

[11]  Y. Huang,et al.  Proton-pump inhibitors and risk of fractures: an update meta-analysis , 2015, Osteoporosis International.

[12]  S. Zhai,et al.  Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials , 2013, PloS one.

[13]  Alexander L. Fohl,et al.  Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? , 2011, World journal of gastrointestinal pharmacology and therapeutics.